600725-69-7

Basic information

• Product Name: N1-cyclopentylbenzene-1,2-diamine
• Synonyms: N1-cyclopentylbenzene-1,2-diamine;1-N-CYCLOPENTYLBENZENE-1,2-DIAMINE
• CAS NO: 600725-69-7
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.25814
• Mol File: 600725-69-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N1-cyclopentylbenzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N1-cyclopentylbenzene-1,2-diamine(600725-69-7)
• EPA Substance Registry System: N1-cyclopentylbenzene-1,2-diamine(600725-69-7)

Safety Data

• Hazardous Substances Data: 600725-69-7(Hazardous Substances Data)

Upstream product

• 55432-25-2 N-cyclopentyl-2-nitroaniline 
• 88-73-3 2-Chloronitrobenzene 
• 1003-03-8 Cyclopentamine 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 600724-46-7 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-carboxylic acid [(R)-2-(4-amino-3,5-dibromo-phenyl)-1-(1-cyclopentyl-1H-benzimidazol-2-yl)-ethyl]-amide 
• 1449690-81-6 C₂₀H₃₀N₂O₃ 

Relevant articles and documents

NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS

The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models.

4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors

We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (Ki 100-fold selectivity against PKA, ROCK and GSK3.